Intended for healthcare professionals

  1. Research
  2. A strategy to reduce...
  3. A strategy to reduce cardiovascular disease by more than 80%
Papers

A strategy to reduce cardiovascular disease by more than 80%

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7404.1419 (Published 26 June 2003) Cite this as: BMJ 2003;326:1419

Data supplement

Related articles

See more

Cited by...

  • Disease overarching mechanisms that explain and predict outcome of patients with high cardiovascular risk: rationale and design of the Berlin Long-term Observation of Vascular Events (BeLOVE) study
  • Polypill cuts major cardiovascular events by a third, study finds
  • Prediction performance of a cardiovascular risk assessment tool using Stanford EHR data repository
  • Genetic Risk Stratification: Tipping Point for Global Primary Prevention of Coronary Artery Disease
  • Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis
  • Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA
  • Nonadherence to Statins and Antihypertensives and Hospitalizations Among Elderly Medicare Beneficiaries With Incident Cancer
  • Associations between interarm differences in blood pressure and cardiovascular disease outcomes: protocol for an individual patient data meta-analysis and development of a prognostic algorithm
  • Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients
  • What next for the cardiovascular polypill?
  • Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease
  • Genetics: Implications for Prevention and Management of Coronary Artery Disease
  • Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
  • Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world retrospective cohort study
  • Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review
  • A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study
  • Is Statin Monotherapy the Perfect Polypill?
  • Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries
  • Stroke survivors', caregivers' and GPs' attitudes towards a polypill for the secondary prevention of stroke: a qualitative interview study
  • Traditional Chinese Exercise for Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials
  • Estimating The Potential Impact Of Insurance Expansion On Undiagnosed And Uncontrolled Chronic Conditions
  • Twenty top papers--the ones that got away and the results of the top six poll
  • Patients views about taking a polypill to manage cardiovascular risk: a qualitative study in primary care
  • Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK
  • Optimal combination secondary prevention drug treatment and stroke outcomes
  • Management of patients with hypertension: general practice and community pharmacy working together
  • A Polypill Strategy to Improve Global Secondary Cardiovascular Prevention: From Concept to Reality
  • Genetics of Coronary Artery Disease
  • Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care
  • General practitioners' use of absolute risk versus individual risk factors in cardiovascular disease prevention: an experimental study
  • Polypill Therapy, Subclinical Atherosclerosis, and Cardiovascular Events--Implications for the Use of Preventive Pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis)
  • "De-Risking" Risk Reduction: Should Coronary Artery Calcium Scoring Be the Gatekeeper to Preventive Pharmacotherapy With the Polypill?
  • Despite Increased Use And Sales Of Statins In India, Per Capita Prescription Rates Remain Far Below High-Income Countries
  • Cost-Effectiveness of Optimal Use of Acute Myocardial Infarction Treatments and Impact on Coronary Heart Disease Mortality in China
  • A statin a day keeps the doctor away: comparative proverb assessment modelling study
  • The Message Is Clear: Prevent as Well as Treat Acute Myocardial Infarction
  • Polypill is not a 'vaccine-like' solution for primary cardiovascular disease prevention in all parts of the world
  • Starting statins for primary prevention of cardiovascular disease
  • The physiological paradox: reframing the polypill as a vaccine for cardiovascular disease
  • Polypill inventor puts product online after failing to get backing from industry
  • Risk Factor Control for Coronary Artery Disease Secondary Prevention in Large Randomized Trials
  • Innovate or die
  • Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
  • A 'Polypill' Aimed At Preventing Cardiovascular Disease Could Prove Highly Cost-Effective For Use In Latin America
  • Genes and Coronary Artery Disease: Where Are We?
  • Achievement of Cardiometabolic Goals in Aware Hypertensive Patients in Spain: Implications for Population Health
  • Polypill remains the only panacea in sight for cardiovascular disease, trial organiser says
  • Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study
  • Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators
  • Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience
  • The polypill: a magic bullet against cardiovascular disease?
  • The causal exposure model of vascular disease
  • The Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): A Cluster Randomized Trial
  • Improving smoking cessation approaches at the individual level
  • NICE hypertension guideline 2011: evidence based evolution
  • 9p21 and the Genetic Revolution for Coronary Artery Disease
  • The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population
  • Translational Research: From Observational Studies to Health Policy: How a Cohort Study Can Help Improve Outcomes After Stroke
  • What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference study
  • Comparative Effectiveness and Cost-Effectiveness of Computed Tomography Screening for Coronary Artery Calcium in Asymptomatic Individuals
  • Increased risk of glucose intolerance and type 2 diabetes with statins
  • Discontinuation of aspirin for secondary prevention
  • Dilemmas of Blood Pressure Management for Heart Failure Prevention
  • Global response to non-communicable disease
  • Recent Advances in Preventive Cardiology and Lifestyle Medicine: A Themed Series
  • Promoting Global Cardiovascular Health: Ensuring Access to Essential Cardiovascular Medicines in Low- and Middle-Income Countries
  • Multidrug Treatment of Type 2 Diabetes: A challenge for compliance
  • Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose
  • Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction
  • Carotid Plaque in Alzheimer Caregivers and the Role of Sympathoadrenal Arousal
  • Potential health impacts of multiple drug prescribing for older people: a case-control study
  • Is estimating lifetime cardiovascular risk useful?
  • The Polypill in the Prevention of Cardiovascular Diseases: Key Concepts, Current Status, Challenges, and Future Directions
  • What Is the Future of Stroke Prevention?: Debate: Polypill Versus Personalized Risk Factor Modification
  • Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future?
  • Outpatient EHR-Based Diabetes Clinical Decision Support That Works: Lessons Learned From Implementing Diabetes Wizard
  • The polypill concept
  • Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease: Findings From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
  • How should we balance individual and population benefits of statins for preventing cardiovascular disease?
  • The polypill concept
  • Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study
  • Reply
  • Prognosis and prognostic research: application and impact of prognostic models in clinical practice
  • Management of blood pressure in primary care
  • Cardiovascular risk: who should we treat, and how much should we stratify?
  • Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India
  • Dyslipidaemia, statins and rheumatoid arthritis
  • Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model
  • Age threshold for vascular prophylaxis by aspirin in patients without diabetes
  • Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines
Back to top